Trial Profile
Phase IB study of TNT009 in patients with Cold Agglutinin Disease
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2019
Price :
$35
*
At a glance
- Drugs Sutimlimab (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Therapeutic Use
- 11 Dec 2017 According to a Bioverativ media release, primary and secondary outcome measures were achieved in the six patients with primary CAgD in the study.
- 11 Dec 2017 According to a Bioverativ media release, six primary CAgD patients data was presented at the 59th Annual Meeting of the American Hematology Society.
- 11 Dec 2017 Results (n=6) presented in a Bioverativ media release.